Literature DB >> 27959637

Immunopathogenesis of Chronic Rhinosinusitis and Nasal Polyposis.

Robert P Schleimer1.   

Abstract

Chronic rhinosinusitis (CRS) is a troublesome, chronic inflammatory disease that affects over 10% of the adult population, causing decreased quality of life, lost productivity, and lost time at work and leading to more than a million surgical interventions annually worldwide. The nose, paranasal sinuses, and associated lymphoid tissues play important roles in homeostasis and immunity, and CRS significantly impairs these normal functions. Pathogenic mechanisms of CRS have recently become the focus of intense investigations worldwide, and significant progress has been made. The two main forms of CRS that have been long recognized, with and without nasal polyps, are each now known to be heterogeneous, based on underlying mechanism, geographical location, and race. Loss of the immune barrier, including increased permeability of mucosal epithelium and reduced production of important antimicrobial substances and responses, is a common feature of many forms of CRS. One form of CRS with polyps found worldwide is driven by the cytokines IL-5 and IL-13 coming from Th2 cells, type 2 innate lymphoid cells, and probably mast cells. Type 2 cytokines activate inflammatory cells that are implicated in the pathogenic mechanism, including mast cells, basophils, and eosinophils. New classes of biological drugs that block the production or action of these cytokines are making important inroads toward new treatment paradigms in polypoid CRS.

Entities:  

Keywords:  acantholysis; acanthosis; allergy; chronic rhinosinusitis; eosinophilic inflammation; epithelial barrier; epithelial-to-mesenchymal transition (EMT); glandular hyperplasia; nasal polyp; sinus disease

Mesh:

Year:  2016        PMID: 27959637      PMCID: PMC5514544          DOI: 10.1146/annurev-pathol-052016-100401

Source DB:  PubMed          Journal:  Annu Rev Pathol        ISSN: 1553-4006            Impact factor:   23.472


  179 in total

1.  Altered sinonasal ciliary dynamics in chronic rhinosinusitis.

Authors:  Bei Chen; Jeffrey Shaari; Steven Eau Claire; James N Palmer; Alexander G Chiu; David W Kennedy; Noam A Cohen
Journal:  Am J Rhinol       Date:  2006 May-Jun

Review 2.  Siglec-8 as a drugable target to treat eosinophil and mast cell-associated conditions.

Authors:  Takumi Kiwamoto; Norihito Kawasaki; James C Paulson; Bruce S Bochner
Journal:  Pharmacol Ther       Date:  2012-06-27       Impact factor: 12.310

Review 3.  The sentinel role of the airway epithelium in asthma pathogenesis.

Authors:  Stephen T Holgate
Journal:  Immunol Rev       Date:  2011-07       Impact factor: 12.988

4.  Age-related differences in the pathogenesis of chronic rhinosinusitis.

Authors:  Seong H Cho; Seung J Hong; Brian Han; Sun H Lee; Lydia Suh; James Norton; David Lin; David B Conley; Rakesh Chandra; Robert C Kern; Bruce K Tan; Atsushi Kato; Anju Peters; Leslie C Grammer; Robert P Schleimer
Journal:  J Allergy Clin Immunol       Date:  2012-01-10       Impact factor: 10.793

5.  Distribution of matrix metalloproteinases MMP-1, MMP-2, MMP-8 and tissue inhibitor of matrix metalloproteinases-2 in nasal polyposis and chronic rhinosinusitis.

Authors:  Ahmet Eyibilen; Sevil Cayli; Ibrahim Aladag; Sema Koç; Levent Gurbuzler; Gulsen Arslan Atay
Journal:  Histol Histopathol       Date:  2011-05       Impact factor: 2.303

6.  Chronic rhinosinusitis and biofilms.

Authors:  Hassan H Ramadan; Jose A Sanclement; John G Thomas
Journal:  Otolaryngol Head Neck Surg       Date:  2005-03       Impact factor: 3.497

7.  Reduced levels of lactoferrin in biofilm-associated chronic rhinosinusitis.

Authors:  Alkis J Psaltis; Peter-John Wormald; Kien R Ha; Lor Wai Tan
Journal:  Laryngoscope       Date:  2008-05       Impact factor: 3.325

8.  T-cell regulation in chronic paranasal sinus disease.

Authors:  Nicholas Van Bruaene; Claudina Angela Pérez-Novo; Tomasz M Basinski; Thibaut Van Zele; Gabriele Holtappels; Natalie De Ruyck; Carsten Schmidt-Weber; Cezmi Akdis; Paul Van Cauwenberge; Claus Bachert; Philippe Gevaert
Journal:  J Allergy Clin Immunol       Date:  2008-06       Impact factor: 10.793

9.  Impaired barrier function in patients with house dust mite-induced allergic rhinitis is accompanied by decreased occludin and zonula occludens-1 expression.

Authors:  Brecht Steelant; Ricard Farré; Paulina Wawrzyniak; Jochen Belmans; Emily Dekimpe; Hanne Vanheel; Laura Van Gerven; Inge Kortekaas Krohn; Dominique M A Bullens; Jan L Ceuppens; Cezmi A Akdis; Guy Boeckxstaens; Sven F Seys; Peter W Hellings
Journal:  J Allergy Clin Immunol       Date:  2016-02-02       Impact factor: 10.793

10.  Migration of regulatory T cells toward airway epithelial cells is impaired in chronic rhinosinusitis with nasal polyposis.

Authors:  Yong Min Kim; Amanda Munoz; Peter H Hwang; Kari C Nadeau
Journal:  Clin Immunol       Date:  2010-07-02       Impact factor: 3.969

View more
  119 in total

Review 1.  The barrier hypothesis and Oncostatin M: Restoration of epithelial barrier function as a novel therapeutic strategy for the treatment of type 2 inflammatory disease.

Authors:  Kathryn L Pothoven; Robert P Schleimer
Journal:  Tissue Barriers       Date:  2017-06-13

Review 2.  Temporary olfactory improvement in chronic rhinosinusitis with nasal polyps after treatment.

Authors:  Dawei Wu; Benjamin S Bleier; Yongxiang Wei
Journal:  Eur Arch Otorhinolaryngol       Date:  2018-07-19       Impact factor: 2.503

3.  Increased TSLP, IL-33, IL-25, IL-19, IL 21 and amphiregulin (AREG) levels in chronic rhinosinusitis with nasal polyp.

Authors:  Murat Dogan; Mustafa Sahin; Cigdem Yenisey
Journal:  Eur Arch Otorhinolaryngol       Date:  2019-03-19       Impact factor: 2.503

4.  Nasal polyp fibroblasts modulate epithelial characteristics via Wnt signaling.

Authors:  Alex Dobzanski; Syed Muaz Khalil; Andrew P Lane
Journal:  Int Forum Allergy Rhinol       Date:  2018-08-17       Impact factor: 3.858

5.  Increased thrombin-activatable fibrinolysis inhibitor levels in patients with chronic rhinosinusitis with nasal polyps.

Authors:  Yoshimasa Imoto; Atsushi Kato; Tetsuji Takabayashi; Whitney Stevens; James E Norton; Lydia A Suh; Roderick G Carter; Ava R Weibman; Kathryn E Hulse; Kathleen E Harris; Anju T Peters; Leslie C Grammer; Bruce K Tan; Kevin Welch; Stephanie Shintani-Smith; David B Conley; Robert C Kern; Shigeharu Fujieda; Robert P Schleimer
Journal:  J Allergy Clin Immunol       Date:  2019-09-25       Impact factor: 10.793

Review 6.  Use of endotypes, phenotypes, and inflammatory markers to guide treatment decisions in chronic rhinosinusitis.

Authors:  Anna G Staudacher; Anju T Peters; Atsushi Kato; Whitney W Stevens
Journal:  Ann Allergy Asthma Immunol       Date:  2020-01-30       Impact factor: 6.347

Review 7.  Human eosinophils and mast cells: Birds of a feather flock together.

Authors:  Piper A Robida; Pier Giorgio Puzzovio; Hadas Pahima; Francesca Levi-Schaffer; Bruce S Bochner
Journal:  Immunol Rev       Date:  2018-03       Impact factor: 12.988

8.  Disruption of Sinonasal Epithelial Nrf2 Enhances Susceptibility to Rhinosinusitis in a Mouse Model.

Authors:  Murugappan Ramanathan; Anuj Tharakan; Venkataramana K Sidhaye; Andrew P Lane; Shyam Biswal; Nyall R London
Journal:  Laryngoscope       Date:  2020-07-06       Impact factor: 3.325

Review 9.  Pathogenic and protective roles of B cells and antibodies in patients with chronic rhinosinusitis.

Authors:  Bruce K Tan; Anju T Peters; Robert P Schleimer; Kathryn E Hulse
Journal:  J Allergy Clin Immunol       Date:  2018-05       Impact factor: 10.793

10.  RNA sequencing and pathway analysis identify tumor necrosis factor alpha driven small proline-rich protein dysregulation in chronic rhinosinusitis.

Authors:  Vijay R Ramakrishnan; Joseph R Gonzalez; Sarah E Cooper; Henry P Barham; Catherine B Anderson; Eric D Larson; Carlyne D Cool; John D Diller; Kenneth Jones; Sue C Kinnamon
Journal:  Am J Rhinol Allergy       Date:  2017-09-01       Impact factor: 2.467

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.